If Bioniche plays their cards right, they too will soon be an early stage, pre clinical, one shot, over dilluted, VP laden, partner-less micro cap Biotech with depleted cash, no revenue, high burn and too many staff. Throw in a 60 million dollar white elephant and an unwanted cattle vaccine and you have the makings of a Biotech set to soar as well. All is good, at least they will
...more